Compare HYFM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFM | ICU |
|---|---|---|
| Founded | 1977 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 9.1M |
| IPO Year | 2020 | N/A |
| Metric | HYFM | ICU |
|---|---|---|
| Price | $0.85 | $4.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.5K | ★ 246.8K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,252,000.00 | N/A |
| Revenue This Year | $57.44 | $93.92 |
| Revenue Next Year | $5.71 | $39.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.79 | $0.22 |
| 52 Week High | $4.78 | $4.93 |
| Indicator | HYFM | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 66.02 |
| Support Level | $0.86 | $2.26 |
| Resistance Level | $1.33 | $4.93 |
| Average True Range (ATR) | 0.10 | 0.53 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 27.44 | 76.08 |
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.